What is the optimal antihypertensive management for a 65-year-old man with type 2 diabetes mellitus (HbA1c 9%), stage 3 chronic kidney disease (estimated glomerular filtration rate 30–59 mL/min) and blood pressure 170/110 mmHg?

Management of Severe Hypertension in a 65-Year-Old Diabetic with Stage 3 CKD

Immediately initiate combination antihypertensive therapy targeting blood pressure <130/80 mmHg using an ACE inhibitor or ARB plus a diuretic, and start an SGLT2 inhibitor (empagliflozin, dapagliflozin, or canagliflozin) regardless of current HbA1c to reduce cardiovascular mortality and slow CKD progression. 1, 2

Immediate Blood Pressure Management

Target blood pressure <130/80 mmHg based on the most recent ACC/AHA and KDIGO guidelines, which prioritize cardiovascular and mortality benefits over older, less aggressive targets. 1

• The 2017 ACC/AHA guideline establishes <130/80 mmHg as the target for all patients with CKD and diabetes, based on SPRINT trial data showing significant reductions in cardiovascular events and all-cause mortality with intensive BP control (target <120 mmHg systolic). 1
• With a presenting BP of 170/110 mmHg, this patient is 40/30 mmHg above target and will require combination therapy with 2-3 antihypertensive agents to achieve control. 1

First-Line Antihypertensive Selection

Start an ACE inhibitor or ARB as the foundation of therapy, as these agents provide both BP control and renoprotection in diabetic CKD. 1, 2

• ACE inhibitors reduce cardiovascular events and all-cause mortality more effectively than ARBs in CKD patients, though ARBs are acceptable if ACE inhibitors are not tolerated. 1
• Titrate to the maximum tolerated dose to achieve optimal renoprotection and BP control. 2, 3
• Monitor serum creatinine and potassium 2-4 weeks after initiation or dose adjustment; an increase in creatinine up to 30% is expected and reflects beneficial hemodynamic changes—do not discontinue therapy unless the rise exceeds 30% or acute kidney injury is suspected. 1, 2

Add a thiazide-like diuretic (chlorthalidone or indapamide) as second-line therapy for volume control, which is critical in CKD-related hypertension. 1

• Loop diuretics may be necessary if stage 3B CKD (eGFR 30-44 mL/min/1.73 m²) is present, as thiazides lose efficacy at lower GFR levels. 1
• Check electrolytes (sodium, potassium) within 1-2 weeks of diuretic initiation to detect hypokalemia or hyponatremia. 1

Consider a calcium channel blocker (amlodipine or nifedipine) as third-line therapy if BP remains uncontrolled on ACE inhibitor/ARB plus diuretic. 1

Critical Medication Pitfalls to Avoid

Never combine an ACE inhibitor with an ARB (dual RAS blockade), as this increases risks of hyperkalemia, hypotension, and acute kidney injury without additional cardiovascular or renal benefit. 1, 4

• The VA NEPHRON-D trial demonstrated that dual RAS blockade in diabetic CKD patients increased hyperkalemia and acute kidney injury without improving outcomes. 4

Avoid NSAIDs entirely, as they worsen renal function, increase BP, and blunt the antihypertensive effects of ACE inhibitors/ARBs in elderly patients with CKD. 4

SGLT2 Inhibitor Initiation for Cardiorenal Protection

Start an SGLT2 inhibitor (empagliflozin 10 mg, dapagliflozin 10 mg, or canagliflozin 100 mg daily) immediately, as these agents reduce CKD progression by ~30%, cardiovascular death by 22-38%, and heart failure hospitalization by 31-39% in diabetic CKD patients. 2, 5

• SGLT2 inhibitors can be initiated at any eGFR ≥20 mL/min/1.73 m² and should be continued even if eGFR declines below this threshold during therapy. 2, 5
• Expect an acute, hemodynamic eGFR decline of 3-10 mL/min/1.73 m² within 2-4 weeks; this is a beneficial hemodynamic effect, not kidney injury—continue the drug unless the decline exceeds 30%. 2, 5
• Recheck eGFR and creatinine 2-4 weeks after SGLT2 inhibitor initiation to document the expected decline and ensure it remains within acceptable limits. 5

Glycemic Control Optimization

Target HbA1c <7.0% in this relatively healthy 65-year-old to reduce microvascular complications, including diabetic nephropathy progression. 1, 2

• The current HbA1c of 9% indicates inadequate glycemic control and requires intensification of diabetes therapy. 2
• The SGLT2 inhibitor will lower HbA1c by 0.5-1.0%, providing both glycemic and cardiorenal benefits. 5
• Consider adding a GLP-1 receptor agonist (dulaglutide, semaglutide, or liraglutide) if additional glucose lowering is needed after SGLT2 inhibitor initiation; these agents reduce HbA1c by 1.6-2.5%, promote weight loss, and provide additional cardiovascular protection. 2, 5
• Recheck HbA1c 3 months after medication changes to assess response to therapy. 5

Additional Nephroprotective Therapy

Consider adding finerenone 10-20 mg daily if albuminuria ≥30 mg/g is present and the patient is on maximally tolerated ACE inhibitor/ARB therapy, as this non-steroidal mineralocorticoid receptor antagonist further reduces CKD progression and cardiovascular events. 2, 5

• Check serum potassium before initiating finerenone and 2-4 weeks after starting; add a potassium binder (patiromer) if K⁺ >5.0 mmol/L. 5
• Finerenone should only be started after SGLT2 inhibitor therapy is established, as SGLT2 inhibitors lower hyperkalemia risk. 5

Monitoring Strategy

Check eGFR and urine albumin-to-creatinine ratio (UACR) every 6 months in stage 3 CKD to monitor disease progression and treatment response. 2, 5

Obtain a basic metabolic panel (sodium, potassium, creatinine, eGFR) 2-4 weeks after any medication change (ACE inhibitor/ARB initiation or dose adjustment, diuretic initiation, SGLT2 inhibitor initiation, or finerenone initiation). 2, 5, 3

Monitor BP at every visit and adjust antihypertensive therapy to maintain target <130/80 mmHg. 3

Lifestyle Modifications

Restrict dietary sodium to <2 g/day to enhance BP control and reduce fluid retention. 5

Limit dietary protein to 0.8 g/kg body weight per day to slow CKD progression. 2, 5

Counsel on smoking cessation if applicable, as smoking accelerates CKD progression and increases cardiovascular risk. 1

Expected Clinical Trajectory

With this comprehensive approach, expect:

• BP control to <130/80 mmHg within 4-8 weeks with combination antihypertensive therapy. 1
• HbA1c reduction of 1.5-2.5% over 3-6 months with SGLT2 inhibitor and potential GLP-1 receptor agonist therapy. 5
• Stabilization or slowing of eGFR decline, potentially postponing progression to stage 4 CKD (eGFR <30 mL/min/1.73 m²) for several years. 2, 5
• 30% reduction in CKD progression, 22-38% reduction in cardiovascular death, and 31-39% reduction in heart failure hospitalization over 2-5 years with SGLT2 inhibitor therapy. 5